Welcome, Guest. Please login or register.
May 26, 2024, 11:06:29 am

Login with username, password and session length

  • Total Members: 6309
  • Latest: Vicki
  • Total Posts: 55126
  • Total Topics: 4851
  • Online Today: 98
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 41
Total: 41


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: High Marks for Zepatier Among Those With Severe Chronic Kidney Disease  (Read 5340 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
Merck’s hepatitis C virus (HCV) regimen Zepatier (grazoprevir/elbasvir) cured the virus at high rates among those with severe chronic kidney disease (CKD), according to medical records from the U.S. Department of Veterans Affairs (VA).

Researchers conducted a retrospective database analysis of 1,528 individuals with genotype 1 or 4 of hep C and stage 3 of CKD (an estimated glomerular filtration rate, or eGFR, between 30 and 59) or stage 4 or 5 or CKD (an eGFR below 30) who were treated with Zepatier for 12 or 16 weeks between February and December 2016. The cohort was drawn from the VA Corporate Data Warehouse, which is a national database of electronic medical records for the VA. All the cohort members had at least one inpatient or outpatient medical visit within a year of receiving hep C treatment and had at least two eGFR test results at least 90 days apart.



© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.